Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with Taxanes in Advanced Gastric Cancer
NCT04563975Phase 2Unknown
- Start
- Jul 2020
- Primary completion
- Dec 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in gastric cancer (GC). Primary endpoint: Disease Control Rate at 12 weeks. Status: unknown.
02
Drugs
toripalimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04563975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04563975.